Announcements

“Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS”
by Emmanuel J. Favaloro, Leonardo Pasalic and Giuseppe Lippi
Antibodies 2022, 11(1), 7; https://doi.org/10.3390/antib11010007
Available online: https://www.mdpi.com/2073-4468/11/1/7

“Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications”
by Guanjie Li, Hiroyuki Suzuki, Teizo Asano, Tomohiro Tanaka, Hiroyoshi Suzuki, Mika K. Kaneko and Yukinari Kato
Antibodies 2022, 11(2), 41; https://doi.org/10.3390/antib11020041
Available online: https://www.mdpi.com/2073-4468/11/2/41

“Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies”
by Brian A. Baldo
Antibodies 2022, 11(1), 17; https://doi.org/10.3390/antib11010017
Available online: https://www.mdpi.com/2073-4468/11/1/17

“Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-C—Can We Match the Puzzle?”
by Snezhina Lazova, Yulia Dimitrova, Diana Hristova, Iren Tzotcheva and Tsvetelina Velikova
Antibodies 2022, 11(2), 25; https://doi.org/10.3390/antib11020025
Available online: https://www.mdpi.com/2073-4468/11/2/25

“Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents”
by Maxime Lecerf, Robin Lacombe, Alexia Kanyavuz and Jordan D. Dimitrov
Antibodies 2022, 11(1), 11; https://doi.org/10.3390/antib11010011
Available online: https://www.mdpi.com/2073-4468/11/1/11

“Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore”
by Chin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu and Tar Choon Aw
Antibodies 2022, 11(2), 38; https://doi.org/10.3390/antib11020038
Available online: https://www.mdpi.com/2073-4468/11/2/38

“New Opportunities in Glycan Engineering for Therapeutic Proteins”
by Xiaotian Zhong, Aaron M. D’Antona, John J. Scarcelli and Jason C. Rouse
Antibodies 2022, 11(1), 5; https://doi.org/10.3390/antib11010005
Available online: https://www.mdpi.com/2073-4468/11/1/5

“Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics”
by Taihei Murakami, Shigefumi Kumachi, Yasuhiro Matsunaga, Miwa Sato, Kanako Wakabayashi-Nakao, Hidekazu Masaki, Ryo Yonehara, Maiko Motohashi, Naoto Nemoto and Masayuki Tsuchiya
Antibodies 2022, 11(1), 10; https://doi.org/10.3390/antib11010010
Available online: https://www.mdpi.com/2073-4468/11/1/10

“Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library”
by Ivette Mendoza-Salazar, Keyla M. Gómez-Castellano, Edith González-González, Ramsés Gamboa-Suasnavart, Stefany D. Rodríguez-Luna, Giovanni Santiago-Casas, María I. Cortés-Paniagua, Sonia M. Pérez-Tapia and Juan C. Almagro
Antibodies 2022, 11(1), 13; https://doi.org/10.3390/antib11010013
Available online: https://www.mdpi.com/2073-4468/11/1/13

“Highly Specific Monoclonal Antibody Targeting the Botulinum Neurotoxin Type E Exposed SNAP-25 Neoepitope”
by Adva Mechaly, Eran Diamant, Ron Alcalay, Alon Ben David, Eyal Dor, Amram Torgeman, Ada Barnea, Meni Girshengorn, Lilach Levin, Eyal Epstein et al.
Antibodies 2022, 11(1), 21; https://doi.org/10.3390/antib11010021
Available online: https://www.mdpi.com/2073-4468/11/1/21

1. “Recombinant Antibody Production Using a Dual-Promoter Single Plasmid System”
by Stefania C. Carrara, David Fiebig, Jan P. Bogen, Julius Grzeschik, Björn Hock and Harald Kolmar
Antibodies 2021, 10(2), 18; https://doi.org/10.3390/antib10020018
Available online: https://www.mdpi.com/2073-4468/10/2/18

2. “Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics”
by Taihei Murakami, Shigefumi Kumachi, Yasuhiro Matsunaga, Miwa Sato, Kanako Wakabayashi-Nakao, Hidekazu Masaki, Ryo Yonehara, Maiko Motohashi, Naoto Nemoto and Masayuki Tsuchiya
Antibodies 2022, 11(1), 10; https://doi.org/10.3390/antib11010010
Available online: https://www.mdpi.com/2073-4468/11/1/10

3. “Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors”
by Shasha Li, Alex J. McCraw, Richard A. Gardner, Daniel I. R. Spencer, Sophia N. Karagiannis and Gerd K. Wagner
Antibodies 2021, 10(4), 44; https://doi.org/10.3390/antib10040044
Available online: https://www.mdpi.com/2073-4468/10/4/44

4. “HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1”
by Marius Gramlich, Henry C. W. Hays, Scott Crichton, Philipp D. Kaiser, Anne Heine, Nicole Schneiderhan-Marra, Ulrich Rothbauer, Dieter Stoll, Sandra Maier and Anne Zeck
Antibodies 2021, 10(1), 11; https://doi.org/10.3390/antib10010011
Available online: https://www.mdpi.com/2073-4468/10/1/11

5. “The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use”
by Rita Tavarozzi and Enrica Manzato
Antibodies 2022, 11(1), 16; https://doi.org/10.3390/antib11010016
Available online: https://www.mdpi.com/2073-4468/11/1/16

6. “Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules”
by Amita Datta-Mannan, Robin Brown, Stephanie Key, Paul Cain and Yiqing Feng
Antibodies 2022, 11(1), 2; https://doi.org/10.3390/antib11010002
Available online: https://www.mdpi.com/2073-4468/11/1/2

7. “Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration”
by Arghavan Soleimanizadeh, Heiko Dinter and Katharina Schindowski
Antibodies 2021, 10(4), 47; https://doi.org/10.3390/antib10040047
Available online: https://www.mdpi.com/2073-4468/10/4/47

8. “Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents”
by Maxime Lecerf, Robin Lacombe, Alexia Kanyavuz and Jordan D. Dimitrov
Antibodies 2022, 11(1), 11; https://doi.org/10.3390/antib11010011
Available online: https://www.mdpi.com/2073-4468/11/1/11

As a leading open access publisher, MDPI provides scholars with a high-quality and rich academic exchange platform by continuously expanding into new and exciting research areas.

In December 2022, MDPI launched five new journals, covering multiple subjects such as life sciences, biology, medicine and pharmacology, social sciences and humanities. These new journals are being edited by established scholars across the world.

If you are interested in creating more open access journals with us to publish cutting-edge research, please send your journal proposal application to newjournal-committee@mdpi.com.

MDPI is pleased to announce that we now display the co-authors’ email addresses in addition to the corresponding author’s email address on the webpage of published papers, protected by Captcha. For more information about this change, please visit the journal’s instructions for authors page. 

We believe this change will facilitate academic discussions and advance our cause of open science and research. The corresponding authors are responsible for communicating with their co-authors and indicating in our system (https://susy.mdpi.com/) if co-authors would prefer for their email addresses not to be displayed.

On 9 February 2023, Clarivate, a global leader in providing trusted insights and analytics, added the Preprint Citation Index to the Web of Science platform, streamlining the research process by allowing researchers to locate and link to preprints alongside other trusted content in the database.

The Preprint Citation Index will act as a bridge to connect cutting-edge preprints with peer-reviewed journal articles published within the Web of Science Core Collection. Alerts can be easily set to monitor new research across several repositories and authors will also be able to include preprints on their Web of Science Research Profile to more accurately display their various research outputs.

As of its launch, the Preprint Citation Index will provide nearly two million preprints from various repositories, including MDPI’s own Preprints.org.

MDPI's Preprints Platform – Preprints.org

To advance Open Science and the fast dissemination of research, MDPI offers researchers a free multidisciplinary preprint platform. Preprints.org accepts submissions from all research areas and offers authors high visibility, permanent archiving, article-level Metrics and immediately citable content by assigning a Digital Object Identifier (DOI) to all preprints.

During submission to any MDPI journal, authors have the option to share their research as a preprint. After an initial screening, the manuscript is available online in 48 hours or less. Once online, preprints can be downloaded, shared, commented on, and cited, providing authors maximum visibility.

We invite you to join the ranks of the over 100k researchers using Preprints.org and share your research.

For more information, please visit Preprints.org.

1. "Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets"
by Lokesh Agrawal, Thanasis Poullikkas, Scott Eisenhower, Carlo Monsanto, Ranjith Kumar Bakku, Min-Hua Chen and Rajkumar Singh Kalra
Antibodies 2021, 10(1), 3; https://doi.org/10.3390/antib10010003
Available online: https://www.mdpi.com/2073-4468/10/1/3

2. "Recombinant Antibody Production Using a Dual-Promoter Single Plasmid System"
by Stefania C. Carrara, David Fiebig, Jan P. Bogen, Julius Grzeschik, Björn Hock and Harald Kolmar
Antibodies 2021, 10(2), 18; https://doi.org/10.3390/antib10020018
Available online: https://www.mdpi.com/2073-4468/10/2/18

3. "Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer"
by Violet Y. Tu, Asma Ayari and Roddy S. O’Connor
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25

4. "Engineered mRNA and the Rise of Next-Generation Antibodies"
by Laura Sanz and Luis Álvarez-Vallina
Antibodies 2021, 10(4), 37; https://doi.org/10.3390/antib10040037
Available online: https://www.mdpi.com/2073-4468/10/4/37

5. "Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo"
by Jessica Bourque and Daniel Hawiger
Antibodies 2022, 11(1), 8; https://doi.org/10.3390/antib11010008
Available online: https://www.mdpi.com/2073-4468/11/1/8

6. "Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries"
by Aric Huang, Wei Jin, Ahmed S. Fahad, Brooklyn K. Mussman, Grazia Paola Nicchia, Bharat Madan, Matheus Oliveira de Souza, J. Daniel Griffin, Jeffrey L. Bennett, Antonio Frigeri et al.
Antibodies 2022, 11(2), 39; https://doi.org/10.3390/antib11020039
Available online: https://www.mdpi.com/2073-4468/11/2/39

7. "Mitochondrial Autoantibodies and the Role of Apoptosis in Pemphigus Vulgaris"
by Dana M. Hutchison, Anna-Marie Hosking, Ellen M. Hong, and Sergei A. Grando
Antibodies 2022, 11(3), 55; https://doi.org/10.3390/antib11030055
Available online: https://www.mdpi.com/2073-4468/11/3/55

8. "Structural Investigation of Therapeutic Antibodies Using Hydroxyl Radical Protein Footprinting Methods"
by Corie Y. Ralston and Joshua S. Sharp
Antibodies 2022, 11(4), 71; https://doi.org/10.3390/antib11040071
Available online: https://www.mdpi.com/2073-4468/11/4/71

We are pleased to announce the Antibodies Editor's Choice Articles published in 2020 and 2021. Editor’s Choice Articles are selected based on suggestions from the academic editors of Antibodies (ISSN: 2073-4468) from around the world. Editors select a small number of articles recently published in the journal that they consider to be of particular interest to readers or important in their respective fields of research. We are delighted to present the Editor's Choice Articles from 2020 and 2021, a curated list of high-quality articles from Antibodies. The full list of Editor’s Choice Articles can be found at the following link: https://www.mdpi.com/journal/antibodies/editors_choice. 

“Monoclonal Antibodies in Cancer Therapy”
by David Zahavi and Louis Weiner
Antibodies 2020, 9(3), 34; https://doi.org/10.3390/antib9030034
Available online: https://www.mdpi.com/2073-4468/9/3/34
Cited by 147 | Viewed by 17551 

“Antibody Conjugates-Recent Advances and Future Innovations”
by Donmienne Leung, Jacqueline M. Wurst, Tao Liu, Ruben M. Martinez, Amita Datta-Mannan and Yiqing Feng
Antibodies 2020, 9(1), 2; https://doi.org/10.3390/antib9010002
Available online: https://www.mdpi.com/2073-4468/9/1/2
Cited by 51 | Viewed by 12315 

“From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry”
by Darja Kanduc
Antibodies 2020, 9(3), 33; https://doi.org/10.3390/antib9030033
Available online: https://www.mdpi.com/2073-4468/9/3/33
Cited by 48 | Viewed by 12455 

“Structure, Function, and Therapeutic Use of IgM Antibodies”
by Bruce A. Keyt, Ramesh Baliga, Angus M. Sinclair, Stephen F. Carroll and Marvin S. Peterson
Antibodies 2020, 9(4), 53; https://doi.org/10.3390/antib9040053
Available online: https://www.mdpi.com/2073-4468/9/4/53
Cited by 45 | Viewed by 10761 

“Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment”
by Rena Liu, Robert J. Oldham, Emma Teal, Stephen A. Beers and Mark S. Cragg
Antibodies 2020, 9(4), 64; https://doi.org/10.3390/antib9040064
Available online: https://www.mdpi.com/2073-4468/9/4/64
Cited by 42 | Viewed by 11394 

“Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations”
by Souad Boune, Peisheng Hu, Alan L. Epstein and Leslie A. Khawli
Antibodies 2020, 9(2), 22; https://doi.org/10.3390/antib9020022
Available online: https://www.mdpi.com/2073-4468/9/2/22
Cited by 25 | Viewed by 9663 

“Complement System: Promoter or Suppressor of Cancer Progression?”
by Margot Revel, Marie V. Daugan, Catherine Sautés-Fridman, Wolf H. Fridman and Lubka T. Roumenina
Antibodies 2020, 9(4), 57; https://doi.org/10.3390/antib9040057
Available online: https://www.mdpi.com/2073-4468/9/4/57
Cited by 21 | Viewed by 4840 

“A Review of Deep Learning Methods for Antibodies”
by Jordan Graves, Jacob Byerly, Eduardo Priego, Naren Makkapati, S. Vince Parish, Brenda Medellin and Monica Berrondo
Antibodies 2020, 9(2), 12; https://doi.org/10.3390/antib9020012
Available online: https://www.mdpi.com/2073-4468/9/2/12
Cited by 21 | Viewed by 11852 

“Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting against Past, Present, and Future Viral Infections”
by Uri Galili
Antibodies 2020, 9(2), 25; https://doi.org/10.3390/antib9020025
Available online: https://www.mdpi.com/2073-4468/9/2/25
Cited by 20 | Viewed by 4329 

“The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs”
by Josée Golay and Ronald P. Taylor
Antibodies 2020, 9(4), 58; https://doi.org/10.3390/antib9040058
Available online: https://www.mdpi.com/2073-4468/9/4/58
Cited by 19 | Viewed by 4898 

“A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation”
by Yutaka Matsuda, Monica Leung, Tatsuya Okuzumi and Brian Mendelsohn
Antibodies 2020, 9(2), 16; https://doi.org/10.3390/antib9020016
Available online: https://www.mdpi.com/2073-4468/9/2/16
Cited by 17 | Viewed by 5788 

“Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease”
by Irina A. Pashnina, Irina M. Krivolapova, Tamara V. Fedotkina, Varvara A. Ryabkova, Margarita V. Chereshneva, Leonid P. Churilov and Valeriy A. Chereshnev
Antibodies 2021, 10(1), 9; https://doi.org/10.3390/antib10010009
Available online: https://www.mdpi.com/2073-4468/10/1/9
Cited by 17 | Viewed by 6924 

“Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19”
by Zheng Cai, Mark I. Greene, Zhiqiang Zhu and Hongtao Zhang
Antibodies 2020, 9(4), 52; https://doi.org/10.3390/antib9040052
Available online: https://www.mdpi.com/2073-4468/9/4/52
Cited by 17 | Viewed by 4795 

“Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents”
by Geert van Tetering, Geert, Mitchell Evers, Chilam Chan, Marjolein Stip and Jeanette Leusen
Antibodies 2020, 9(4), 70; https://doi.org/10.3390/antib9040070
Available online: https://www.mdpi.com/2073-4468/9/4/70
Cited by 14 | Viewed by 4550 

“IgE Antibodies against Cancer: Efficacy and Safety”
by Jitesh Chauhan, Alex J. McCraw, Mano Nakamura, Gabriel Osborn, Heng Sheng Sow, Vivienne F. Cox, Chara Stavraka, Debra H. Josephs, James F. Spicer, Sophia N. Karagiannis et al.
Antibodies 2020, 9(4), 55; https://doi.org/10.3390/antib9040055
Available online: https://www.mdpi.com/2073-4468/9/4/55
Cited by 13 | Viewed by 5176 

“Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer”
by Violet Y. Tu, Asma Ayari and Roddy S. O’Connor
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25
Cited by 12 | Viewed by 4200 

“Utilizing Immunocytokines for Cancer Therapy”
by Erin Runbeck, Silvia Crescioli, Sophia N. Karagiannis and Sophie Papa
Antibodies 2021, 10(1), 10; https://doi.org/10.3390/antib10010010
Available online: https://www.mdpi.com/2073-4468/10/1/10
Cited by 11 | Viewed by 4707 

“Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies”
by Josée Golay and Alain E. Andrea
Antibodies 2020, 9(2), 17; https://doi.org/10.3390/antib9020017
Available online: https://www.mdpi.com/2073-4468/9/2/17
Cited by 10 | Viewed by 5100 

“Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review”
by Mahdi Alsaleem
Antibodies 2020, 9(4), 60; https://doi.org/10.3390/antib9040060
Available online: https://www.mdpi.com/2073-4468/9/4/60
Cited by 10 | Viewed by 5880 

“IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases?”
by Christophe Pellefigues
Antibodies 2020, 9(3), 47; https://doi.org/10.3390/antib9030047
Available online: https://www.mdpi.com/2073-4468/9/3/47
Cited by 10 | Viewed by 3813 

“Antibody Screening by Microarray Technology—Direct Identification of Selective High-Affinity Clones”
by Martin Paul and Michael G. Weller
Antibodies 2020, 9(1), 1; https://doi.org/10.3390/antib9010001
Available online: https://www.mdpi.com/2073-4468/9/1/1
Cited by 9 | Viewed by 5988 

“Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors”
by Vladimir Voynov, Paul J. Adam, Andrew E. Nixon and Justin M. Scheer
Antibodies 2020, 9(4), 65; https://doi.org/10.3390/antib9040065
Available online: https://www.mdpi.com/2073-4468/9/4/65
Cited by 9 | Viewed by 4841 

“Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics”
by Xiaotian Zhong and Aaron M. D’Antona
Antibodies 2021, 10(2), 13; https://doi.org/10.3390/antib10020013
Available online: https://www.mdpi.com/2073-4468/10/2/13
Cited by 9 | Viewed by 5743 

“The Course of SARS-COV2 Infection Was Not Severe in a Crohn’s Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection”
by Francis Okeke, Anjali Mone and Arun Swaminath
Antibodies 2020, 9(3), 42; https://doi.org/10.3390/antib9030042
Available online: https://www.mdpi.com/2073-4468/9/3/42
Cited by 8 | Viewed by 4231 

“Introduction to Antibody-Drug Conjugates”
by Mark C. Pettinato
Antibodies 2021, 10(4), 42; https://doi.org/10.3390/antib10040042
https://www.mdpi.com/2073-4468/10/4/42
Cited by 8 | Viewed by 3767 

“An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer”
by Fazrena Nadia Md Akhir, Mohd Hezmee Mohd Noor, Keith Weng Kit Leong, Jamileh A. Nabizadeh, Helga D. Manthey, Stefan E. Sonderegger, Jenny Nga Ting Fung, Crystal E. McGirr, Ian A. Shiels, Paul C. Mills et al.
Antibodies 2021, 10(1), 2; https://doi.org/10.3390/antib10010002
Available online: https://www.mdpi.com/2073-4468/10/1/2
Cited by 7 | Viewed by 3239 

“From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry”
by Darja Kanduc
Antibodies 2021, 10(4), 36; https://doi.org/10.3390/antib10040036
Available online: https://www.mdpi.com/2073-4468/10/4/36
Cited by 6 | Viewed by 3821 

“Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2”
by Jeffrey V. Leyton
Antibodies 2020, 9(3), 32; https://doi.org/10.3390/antib9030032
https://www.mdpi.com/2073-4468/9/3/32
Cited by 6 | Viewed by 4632 

“HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1”
by Marius Gramlich, Henry C. W. Hays, Scott Crichton, Philipp D. Kaiser, Anne Heine, Nicole Schneiderhan-Marra, Ulrich Rothbauer, Dieter Stoll, Sandra Maier and Anne Zeck
Antibodies 2021, 10(1), 11; https://doi.org/10.3390/antib10010011
Available online: https://www.mdpi.com/2073-4468/10/1/11
Cited by 6 | Viewed by 3507 

“Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective”
by Andrew T. Lucas, Amber Moody, Allison N. Schorzman and William C. Zamboni
Antibodies 2021, 10(3), 30; https://doi.org/10.3390/antib10030030
Available online: https://www.mdpi.com/2073-4468/10/3/30
Cited by 6 | Viewed by 4572 

“Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy”
by Yasmin Jenkins, Joanna Zabkiewicz, Oliver Ottmann and Nicholas Jones
Antibodies 2021, 10(2), 17; https://doi.org/10.3390/antib10020017
Available online: https://www.mdpi.com/2073-4468/10/2/17
Cited by 6 | Viewed by 4406 

“Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets”
by Lokesh Agrawal, Thanasis Poullikkas, Scott Eisenhower, Carlo Monsanto, Ranjith Kumar Bakku, Min-Hua Chen and Rajkumar Singh Kalra
Antibodies 2021, 10(1), 3; https://doi.org/10.3390/antib10010003
Available online: https://www.mdpi.com/2073-4468/10/1/3
Cited by 5 | Viewed by 5233 

“New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis”
by Roberto Lande, Raffaella Palazzo, Anna Mennella, Immacolata Pietraforte, Marius Cadar, Katia Stefanantoni, Curdin Conrad, Valeria Riccieri and Loredana Frasca
Antibodies 2021, 10(2), 12; https://doi.org/10.3390/antib10020012
Available online: https://www.mdpi.com/2073-4468/10/2/12
Cited by 4 | Viewed by 3213

We are pleased to announce the launch of a new initiative—the MDPI Special Issue Mentor Program.

This program will enable early career researchers (who must hold a Ph.D. in a related field) to experience editing a Special Issue in MDPI journals, under the mentorship of our experienced Editorial Board Members or other experienced scientists. The mentor program will provide an excellent opportunity for early career scientists to gain editorial experience, and to cultivate their ability to edit scientific research.

The mentee’s responsibilities include:

• Proposing a Special Issue title and assisting the mentor in preparing a summary (around 200–400 words) and 3–10 keywords describing the background, importance, and goal of the Issue;
• Writing a brief promotion plan for the Special Issue;
• Preparing a list of scholars who may be interested in the Issue and personally e-mailing invitations on behalf of Guest Editors;
• Writing an editorial for the online Special Issue together with the mentor.

The mentor’s responsibilities include:

• Conducting a final check before the Special Issue is published online;
• Performing editorial control of the Special Issue and quality control of the publications, both of which must be carried out in a timely manner;
• Providing suggestions to younger scholars if they have any doubts or concerns regarding submissions;
• Organizing video calls with young scholars and the Editorial Office regularly to discuss problems and improvement suggestions for the Special Issue;
• Making and submitting decisions regarding submissions with the assistance of mentees.

Certificates and awards:
After the Special Issue closes, the Editorial Office will provide official certificates for all the mentors and early career researchers.

If you are interested in this opportunity, please send your Special Issue proposal to the Editorial Office of a journal you choose, and we will discuss the process (i.e., mentor collaboration, Special Issue topic feasibility analysis, etc.) in further detail. The full list of MDPI journals is as follows: https://www.mdpi.com/about/journals.

In addition to the new Special Issue Mentor Program, we will continue to welcome all Special Issue proposals focusing on hot research topics.

MDPI has just become the first open access (OA) publisher to reach the milestone of one million articles published. That is one million articles freely available to all, to circulate and build upon! We are proud to share this special moment with the global scientific community.

This landmark has been reached thanks to the immeasurable support of more than 600,000 expert reviewers, 66,000 editorial board members and 6700 hard-working colleagues across MDPI’s global offices.

Within more than 25 years of publishing, our journals received 2.1 million manuscripts and generated 4.6 million peer review reports to get to one million papers published.

Reaching the milestone of one million articles published reinforces our mission to remove any existing barriers and to make scientific research accessible to all. Since its inception, MDPI’s goal has been to create reliable processes to make science open. This is a path towards facilitating the dissemination of novel insights in scientific communities.

Regular feedback from authors and reviewers shows that our service is greatly appreciated and needed. At the same time, the feedback helps us identify areas for further improvement.

As it stands, a significant share of published research findings remain closed access. More than half of the content published with the most well-known legacy publishers stays behind a paywall, and that is not including articles published in hybrid OA journals, or made available months or years after publication.

A new policy announced by the US administration in August 2022 requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. While the new policy does not mandate articles be published under an open access license, it is aligned with the open access movement in removing all barriers to research. Similarly, some of the most advanced research institutions in the world intend to have all funded research articles published in open access by 2025.

MDPI is proud to be the leading agent of the transition to open access.

"Thanks a Million" to all the contributors!

We are pleased to announce that the website of the MDPI Sustainability Foundation has been revamped! For the past couple of months, our UX UI team and front-end developers have been working hard to launch the website in time for the opening of the Sustainability Awards nominations.

The website is not the only thing that has had a remodeling. Indeed, the format of the Emerging Sustainability Leader Award (ESLA) has been updated. ESLA is now a competition open to individual researchers or start-ups founded by researchers under the age of 35. Nominee applications will go through 2 rounds of selection until the final 3 are decided. The finalists will then be invited to give pitch presentations during the Award Ceremony to win either first place (10,000 USD) or runner-up (2 x 5000 USD).

The World Sustainability Award, on the other hand, remains the same: a total prize money of 100,000 USD is up for grabs by senior individual researchers or groups of researchers from the international research community.

Nominations for both the World Sustainability Award and the Emerging Sustainability Leader award are now open! Check out our new website for more information on how to nominate.